# 2nd Line Gemcitabine Monotherapy for Transitional Cell Carcinoma of Urothelium (TCC) After CDDP Regimen

> **NCT00191971** · PHASE2 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 40 (—)

## Conditions studied

- Urologic Neoplasms
- Carcinoma, Transitional Cell

## Interventions

- **DRUG:** Gemcitabine

## Key facts

- **NCT ID:** NCT00191971
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-01
- **Primary completion:** —
- **Final completion:** 2006-09
- **Target enrollment:** 40 (—)
- **Last updated:** 2007-11-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00191971

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00191971, "2nd Line Gemcitabine Monotherapy for Transitional Cell Carcinoma of Urothelium (TCC) After CDDP Regimen". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00191971. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*